Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether patients with locally advanced pancreatic
cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to
patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.